Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis

Clinical Rheumatology

Volumn 29, Issue 5, 2010, Pages 487-493

  Tesija Kuna, Andrea ^a   Grazio, Simeon ^a   Miler, Marijana ^a   Vukasovic, Ines ^a   Peric, Porin ^b   Vrkic, Nada ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antibodies against mutated citrullinated vimentin; Antibodies targeting citrullinated peptides; Psoriatic arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ENTHESITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL STATUS; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; POLYARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ADULT; AGED; ANTIBODIES; ARTHRITIS, PSORIATIC; AUTOANTIBODIES; CASE-CONTROL STUDIES; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDES; PREVALENCE; VIMENTIN;

EID: 77950866412     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1345-2     Document Type: Article

References (45)

1. DD Gladman C Antoni P Mease DO Clegg P Nash 2005 Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics Ann Rheum Dis 64 Suppl 14 17
2. DD Gladman R Shuckett ML Russell JC Thorne RK Schachter 1987 Psoriatic arthritis-an analysis of 220 patients Q J Med 62 127 141 1:STN:280: DyaL1c%2Fhs1yhtA%3D%3D 3659255 (Pubitemid 17042878)
3. JC Torre-Alonso A Rodrigues-Perez JM Arribas-Castrillom J Ballina Garcia JL Riestra Noriega C Lopez Larrea 1991 Psoriatic arthritis (PA): a clinical immunologic and radiological study Brit J Rheumatol 30 245 250 10.1093/rheumatology/30.4.245 1:STN:280:DyaK3Mzit1Kjug%3D%3D
4. NJ McHugh C Balachrishnan SM Jones 2003 Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study Rheumatology Oxford 42 778 783 10.1093/rheumatology/keg217 1:STN:280:DC%2BD3s3kvVGltA%3D%3D 12730539 (Pubitemid 37220911)
5. JP Riedmann S Munoz A Kavanaugh 2005 The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis-a systematic review Clin Exp Rheumatol 23 Suppl. 39 S69 S76 (Pubitemid 46657513)
6. J Rönnelid MC Wick J Lampa S Lindblad B Nordmark L Klareskog RF van Vollenhoven 2005 Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression Ann Rheum Dis 64 1744 1749 10.1136/ard.2004.033571 15843452 (Pubitemid 41667149)
7. FA Van Gaalen SP Linn-Rasker WJ van Venrooij BAW de Jong FC Breedveld CL Verweij, et al. 2004 Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis Arthritis Rheum 50 709 715 10.1002/art.20044 15022309 (Pubitemid 38326168)
8. S Nijenhuis AJ Zendman ER Vossenaar GJ Pruijn WJ van Venrooij 2004 Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker Clin Chim Acta 350 17 34 10.1016/j.cccn.2004.07.016 1:CAS:528:DC%2BD2cXpsVKnu70%3D 15530456 (Pubitemid 39458243)
9. C Masson-Bessiere M Sebbag E Girbal-Neuhauser L Nogueira C Vincent T Senshu G Serre 2001 The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin J Immunol 166 6 4177 4184 1:CAS:528: DC%2BD3MXitVGmtr8%3D 11238669 (Pubitemid 32224951)
10. X Chang R Yamada A Suzuki Y Kochi T Sawada K Yamamoto 2005 Citrullination of fibronectin in rheumatoid arthritis synovial tissue Rheumatology 44 11 1374 1382 10.1093/rheumatology/kei023 1:CAS:528:DC%2BD2MXhtFCjtL7M 16105911 (Pubitemid 41631860)
11. A Suzuki R Yamad M Ohtake-Yamanaka Y Okazaki T Sawada K Yamamoto 2005 Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis Biochem Biophys res Commun 333 418 426 10.1016/j.bbrc.2005. 05.137 1:CAS:528:DC%2BD2MXlsVChtbk%3D 15950180 (Pubitemid 40848307)
12. A Kinloch V Tatzer R Wait D Peston K Lundberg P Donatien, et al. 2005 Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis Arthritis Res Ther 7 R1421 R1429 10.1186/ar1845 1:CAS:528:DC%2BD2MXht1Wmsr%2FL 16277695
13. ER Vossenaar N Despres E Lapointe A van der Heijden M Lora T Senshu, et al. 2004 Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin Arthritis Res Ther 6 2 R142 R150 10.1186/ar1149 1:CAS:528: DC%2BD2cXktValtLw%3D 15059278
14. SV Strelkov H Herrmann U Aebi 2003 Molecular architecture of intermediate filaments Bioassays 25 243 251 10.1002/bies.10246 1:CAS:528: DC%2BD3sXisVWntr8%3D (Pubitemid 36314111)
15. H Bang K Egerer A Gauliard K Lüthke PE Rudolph G Fredenhagen, et al. 2007 Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis Arthritis Rheum 56 8 2503 2511 10.1002/art.22817 1:CAS:528:DC%2BD2sXhtVWqu7rK 17665451 (Pubitemid 47237269)
16. C Dejaco W Klotz H Larcher C Duftner M Schirmer M Herold 2006 Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis Arthritis Res Ther 8 4 R119 10.1186/ar2008 16859519
17. L Soos Z Szekanecz Z Szabo A Fekete M Zeher IF Horvath, et al. 2007 Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis J Rheumatol 34 1658 1663 1:CAS:528:DC%2BD2sXhtVSkt7nK 17611988 (Pubitemid 47267606)
18. L Mathsson M Mullazehi MC Wick O Sjöberg R van Vollenhoven L Klareskog J Rönnelid 2008 Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides Arthritis Rheum 58 36 45 10.1002/art.23188 1:CAS:528:DC%2BD1cXhslOjsb8%3D 18163519
19. H Poulsom PJ Charles 2008 Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis Clinic Rev Allerg Immunol 34 4 10 10.1007/s12016-007-8016-3 1:CAS:528: DC%2BD1cXkt1Kmtb8%3D
20. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith, et al. 1995 American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727 735 10.1002/art.1780380602 1:STN:280:DyaK2M3pvVSmtA%3D%3D 7779114
21. L Heuft-Dorenbosch A Spoorenberg A van Tubergen R Landewé H van der Tempel H Mielantset, et al. 2003 Assessment of enthesitis in ankylosing spondylitis Ann Rheum Dis 62 127 132 10.1136/ard.62.2.127 1:STN:280: DC%2BD3s%2FktlCqsQ%3D%3D 12525381 (Pubitemid 36135387)
22. ML Prevoo MA van't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44 48 10.1002/art. 1780380107 1:STN:280:DyaK2M7hvVeqtA%3D%3D 7818570
23. M Blackmore DD Gladman J Husted J Long VT Farewell 1995 Measuring health status in psoriatic arthritis: the health assessment questionnaire and its modification J Rheumatol 22 886 893 1:STN:280:DyaK287nt1Crug%3D%3D 8587077
24. R Marks SP Barton D Shuttleworth AY Finlay 1989 Assessment of disease progress in psoriasis Arch Dermatol 125 235 240 10.1001/archderm.125.2.235 1:STN:280:DyaL1M7hslWrsg%3D%3D 2643928 (Pubitemid 19070211)
25. T Fredriksson U Pettersson 1978 Severe psoriasis: oral therapy with a new retinoid Dermatologica 157 238 244 10.1159/000250839 1:STN:280: DyaE1M%2Fgtlymtg%3D%3D 357213 (Pubitemid 8387357)
26. K Webster D Cella K Yost 2003 The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation Health Qual Life Outcomes 16 79 10.1186/1477-7525-1-79 (Pubitemid 39111917)
27. D Cella S Yount M Sorensen E Chartash N Sengupta J Grober 2005 Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis J Rheumatol 32 811 819 15868614 (Pubitemid 40676488)
28. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara, et al. 2003 Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 35 45 10.1002/art.10697 1:CAS:528:DC%2BD3sXhtFGnsb0%3D 12528101 (Pubitemid 36091645)
29. ER Vossenar TR Radstake A van der Heijden MA van Mansum C Dieteren DJ de Rooij, et al. 2004 Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages Ann Rheum Dis 63 373 381 10.1136/ard.2003.012211 (Pubitemid 38453302)
30. K Brickmann BJ Yazdani-Biuki T Müller WB Graninger HP Brezinschek 2006 Anti-mutated-citrullinated-vimentin antibodies (MCV) in psoriatic arthritis (Abstract) Ann Rheum Dis 65 Suppl II 648
31. N Fabien NO Olson J Goetz C Johanet A Escande N Bardin, et al. 2008 Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study Clinic Rev Allerg Immunol 34 40 44 10.1007/s12016-008-8073-2 1:CAS:528:DC%2BD1cXkt1Kmtbg%3D
32. GM Alenius E Berglin S Rantapää-Dahlqvist 2006 Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation Ann Rheum Dis 65 398 400 10.1136/ard.2005.040998 1:CAS:528:DC%2BD28XisFCjtbc%3D 16096328 (Pubitemid 43268233)
33. N Inanc E Dalkilic S Kamali E Kasapoglu-Günal Y Elbir H Direskeneli M Inanc 2007 Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis Clin Rheumatol 26 17 23 10.1007/s10067-006-0214-5 1:STN:280: DC%2BD2s%2FoslGlug%3D%3D 16538391 (Pubitemid 46020016)
34. L Bogliolo C Alpini R Caporali CA Scirè R Moratti C Montecucco 2005 Antibodies to cyclic citrullinated peptides in psoriatic arthritis J Rheumatol 32 511 515 1:CAS:528:DC%2BD2MXivVyns7Y%3D 15742445 (Pubitemid 40381424)
35. BV Cruyssen IEA Hoffman H Zmierczak M Van den Berghe E Kruithof L De Rycke, et al. 2005 Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis Ann Rheum Dis 64 1145 1149 10.1136/ard.2004.032177 (Pubitemid 41113348)
36. NJ McHugh C Balachrishnan SM Jones 2003 Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study Rheumatology 42 778 783 10.1093/rheumatology/keg217 1:STN:280:DC%2BD3s3kvVGltA%3D%3D 12730539 (Pubitemid 37220911)
37. S Rantapaa-Dahlqvist BA de Jong E Berglin G Hallmans G Wadell H Stenlund, et al. 2003 Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 48 2741 2749 10.1002/art.11223 14558078 (Pubitemid 37280601)
38. MM Nielen D van Schaardenburg HW Reesink RJ van de Stadt IE van der Horst-Bruinsma MH de Koning, et al. 2004 Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum 50 380 386 10.1002/art.20018 14872479 (Pubitemid 38198821)
39. L Innala H Kokkonen C Eriksson E Jiddell E Berglin S Rantapaa-Dahlqvist 2008 Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides J Rheumatol 35 1 7 (Pubitemid 351813144)
40. A Kastbom G Strandberg A Lindroos T Skogh 2004 Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) Ann Rheum Dis 63 1085 1089 10.1136/ard.2003.016808 1:CAS:528:DC%2BD2cXnvFWkt7s%3D 15308517 (Pubitemid 39120359)
41. TR Mikuls JR O'Dell JA Stoner LA Parrish WP Arend JM Norris VM Holers 2004 Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody Arthritis Rheum 50 3776 3782 10.1002/art.20659 1:CAS:528:DC%2BD2MXls1ehtg%3D%3D 15593224 (Pubitemid 39643924)
42. P Caramaschi D Biasi E Tonolli S Pieropan N Martinelli A Carletto, et al. 2005 Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment Rheumatol Int 26 58 62 10.1007/s00296-004-0571-9 1:CAS:528:DC%2BD2MXhtFCrtL7E 15726373 (Pubitemid 41531516)
43. Y Braun-Moscovici D Markovits O Zinder D Schapira A Rozin M Ehrenburg, et al. 2006 Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis J Rheumatol 33 497 500 1:CAS:528:DC%2BD28XivVGhtr4%3D 16511906 (Pubitemid 43334571)
44. HA Chen KC Lin CH Chen HT Liao HP Wang HN Chang, et al. 2006 The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis 65 35 39 10.1136/ard.2005.038851 1:CAS:528:DC%2BD28Xnt12htA%3D%3D 15975966 (Pubitemid 41815636)
45. C Alessandri M Bombardieri N Pap M Cinquini L Magrini A Tincani G Valesini 2004 Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis 63 1218 1221 10.1136/ard.2003.014647 1:CAS:528:DC%2BD2cXovFOmsrg%3D 15361374 (Pubitemid 39273496)